 Connection
Nishant Rana to Signal Transduction
This is a "connection" page, showing publications Nishant Rana has written about Signal Transduction.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.188 |
|
|
|
-
Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells. Nat Immunol. 2025 Jan; 26(1):92-104.
Score: 0.084
-
Schelker RC, Fioravanti J, Mastrogiovanni F, Baldwin JG, Rana N, Li P, Chen P, Vadász T, Spolski R, Heuser-Loy C, Slavkovic-Lukic D, Noronha P, Damiano G, Raccosta L, Maggioni D, Pullugula S, Lin JX, Oh J, Grandinetti P, Lecce M, Hesse L, Kocks E, Martín-Santos A, Gebhard C, Telford WG, Ji Y, Restifo NP, Russo V, Rehli M, Herr W, Leonard WJ, Gattinoni L. LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduct Target Ther. 2024 08 09; 9(1):199.
Score: 0.082
-
Huerta Arana M, Klapproth H, Stanczak MA, Bopp L, Witschurke K, Seitz R, Lopéz Martinez M, Zamek J, Henschke S, Rana N, O'Sullivan D, Steinkamp J, Lackmann JW, Damsky W, von Stebut E, Sanin DE, Zigrino P, Klein Geltink RI, Pearce EJ, Pearce EL, Fabri M. A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease. Sci Adv. 2026 May 29; 12(22):eaea0773.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|